Immune checkpoint inhibitor-induced acquired haemophilia: A pharmacovigilance analysis of the FDA adverse event reporting system. - Suppr | 超能文献

Immune checkpoint inhibitor-induced acquired haemophilia: A pharmacovigilance analysis of the FDA adverse event reporting system.

作者信息

Moore Donald C, Elmes Joseph B, Arnall Justin R, Strassels Scott A, Patel Jai N

机构信息

Atrium Health, Department of Pharmacy, Levine Cancer Institute, Charlotte, North Carolina, USA.

Atrium Health, Department of Pharmacy, Levine Cancer Institute, Concord, North Carolina, USA.

出版信息

Haemophilia. 2022 Sep;28(5):e145-e148. doi: 10.1111/hae.14632. Epub 2022 Jul 27.

DOI:10.1111/hae.14632

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Immune checkpoint inhibitor-induced acquired haemophilia: A pharmacovigilance analysis of the FDA adverse event reporting system.

Haemophilia. 2022 Sep;28(5):e145-e148. doi: 10.1111/hae.14632. Epub 2022 Jul 27.

2

Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system.获得性血栓性血小板减少性紫癜与免疫检查点抑制剂相关：FDA 不良事件报告系统的真实世界研究。

Int Immunopharmacol. 2022 Sep;110:109015. doi: 10.1016/j.intimp.2022.109015. Epub 2022 Jul 6.

3

Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program.与程序性死亡受体-1（PD-1）和程序性死亡配体-1（PD-L1）抑制剂相关的大疱性疾病：来自药物不良事件和报告项目研究的美国食品药品监督管理局不良事件报告系统的药物警戒分析

J Am Acad Dermatol. 2020 Sep;83(3):955-957. doi: 10.1016/j.jaad.2020.01.059. Epub 2020 Jan 31.

4

Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.免疫检查点抑制剂相关的免疫相关不良事件：FDA 不良事件报告系统的更新综合比例失调分析。

Int Immunopharmacol. 2021 Jun;95:107498. doi: 10.1016/j.intimp.2021.107498. Epub 2021 Mar 13.

5

Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.免疫检查点抑制剂联合或不联合化疗的肾毒性：利用美国 FARES 数据库进行的观察性、回顾性、药物警戒研究。

Cancer Med. 2021 Dec;10(24):8754-8762. doi: 10.1002/cam4.4343. Epub 2021 Nov 29.

6

Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis.免疫检查点抑制剂引起的眼部不良事件：一项全面的药物警戒分析。

Ocul Immunol Inflamm. 2022 Jan 2;30(1):191-197. doi: 10.1080/09273948.2020.1773867. Epub 2020 Aug 4.

7

Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.免疫检查点抑制剂相关的心血管毒性：FDA 不良事件报告系统的更新综合不成比例分析。

J Clin Pharm Ther. 2022 Oct;47(10):1576-1584. doi: 10.1111/jcpt.13707. Epub 2022 Jun 20.

8

Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.免疫检查点抑制剂使用后的结肠炎：向 FDA 不良事件报告系统提交的自发报告的真实世界分析。

Int Immunopharmacol. 2020 Jul;84:106601. doi: 10.1016/j.intimp.2020.106601. Epub 2020 May 16.

9

Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis.骨骨折作为一种新型免疫相关不良事件与免疫检查点抑制剂：病例系列和大规模药物警戒分析。

Int J Cancer. 2021 Aug 1;149(3):675-683. doi: 10.1002/ijc.33592. Epub 2021 May 4.

10

Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.免疫检查点抑制剂的内分泌毒性：一项利用美国食品和药物管理局不良事件报告系统的真实世界研究。

J Immunother Cancer. 2019 Nov 6;7(1):286. doi: 10.1186/s40425-019-0754-2.

引用本文的文献

1

Immunotherapy-associated hemostatic abnormalities: bleeding and thrombotic complications.免疫治疗相关的止血异常：出血和血栓形成并发症。

Ann Hematol. 2025 Jul;104(7):3537-3551. doi: 10.1007/s00277-025-06482-z. Epub 2025 Jul 1.

2

A Rare Case of Hemophilia: Acquired Factor VIII Deficiency.血友病罕见病例：获得性VIII因子缺乏症

Cureus. 2024 Jun 14;16(6):e62407. doi: 10.7759/cureus.62407. eCollection 2024 Jun.

3

Rare Immune-Related Adverse Events (irAEs): Approach to Diagnosis and Management.罕见的免疫相关不良事件（irAEs）：诊断和管理方法。

Pharmaceut Med. 2024 Jan;38(1):25-38. doi: 10.1007/s40290-023-00508-5. Epub 2024 Jan 9.